🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 09/10/2017 | 155,85 | 157,29 | 154,46 | 155,55 | +0,29% | 1,82% | 1.141.900 |
| 06/10/2017 | 152,43 | 156,46 | 152,31 | 155,10 | +1,84% | 2,72% | 1.551.100 |
| 05/10/2017 | 153,09 | 153,57 | 150,96 | 152,30 | -0,14% | 1,70% | 1.273.700 |
| 04/10/2017 | 152,26 | 153,82 | 151,36 | 152,51 | +0,00% | 1,62% | 970.200 |
| 03/10/2017 | 152,21 | 152,99 | 150,18 | 152,51 | +0,18% | 1,85% | 995.000 |
| 02/10/2017 | 151,23 | 153,17 | 150,10 | 152,23 | +0,12% | 2,03% | 2.057.700 |
| 29/09/2017 | 151,21 | 152,34 | 149,18 | 152,04 | +1,62% | 2,09% | 1.500.200 |
| 28/09/2017 | 148,60 | 150,99 | 147,60 | 149,62 | +0,37% | 2,28% | 2.111.100 |
| 27/09/2017 | 148,86 | 150,98 | 147,30 | 149,07 | +0,41% | 2,47% | 2.112.300 |
| 26/09/2017 | 149,85 | 150,82 | 148,00 | 148,46 | -0,43% | 1,88% | 1.762.000 |
| 25/09/2017 | 151,19 | 152,79 | 148,77 | 149,10 | -1,43% | 2,66% | 1.741.200 |
| 22/09/2017 | 151,54 | 152,07 | 148,58 | 151,26 | -0,53% | 2,30% | 1.269.900 |
| 21/09/2017 | 153,22 | 153,29 | 151,69 | 152,06 | -0,43% | 1,04% | 808.200 |
| 20/09/2017 | 153,29 | 155,14 | 151,51 | 152,72 | -0,18% | 2,37% | 1.931.400 |
| 19/09/2017 | 153,27 | 154,10 | 151,60 | 153,00 | -0,13% | 1,63% | 1.428.300 |
| 18/09/2017 | 153,59 | 155,11 | 151,79 | 153,20 | -0,27% | 2,16% | 1.386.900 |
| 15/09/2017 | 153,86 | 155,95 | 152,64 | 153,61 | +0,15% | 2,15% | 3.112.900 |
| 14/09/2017 | 156,05 | 156,56 | 152,88 | 153,38 | -2,18% | 2,36% | 1.461.700 |
| 13/09/2017 | 156,79 | 157,95 | 155,70 | 156,80 | -0,01% | 1,44% | 995.100 |
| 12/09/2017 | 156,65 | 157,79 | 155,40 | 156,82 | -0,63% | 1,53% | 800.600 |
| 11/09/2017 | 161,05 | 161,46 | 155,33 | 157,81 | -0,64% | 3,81% | 1.519.900 |
| 08/09/2017 | 159,61 | 161,44 | 157,38 | 158,83 | -0,36% | 2,54% | 1.064.700 |
| 07/09/2017 | 157,08 | 159,68 | 155,52 | 159,41 | +1,48% | 2,65% | 1.236.000 |
| 06/09/2017 | 159,50 | 160,80 | 156,91 | 157,08 | -1,25% | 2,44% | 1.328.400 |
| 05/09/2017 | 161,37 | 162,07 | 157,00 | 159,07 | -1,95% | 3,14% | 1.327.000 |
| 01/09/2017 | 160,76 | 163,64 | 158,85 | 162,24 | +1,06% | 2,98% | 1.708.700 |
| 31/08/2017 | 156,57 | 160,85 | 154,03 | 160,54 | +2,72% | 4,36% | 3.329.500 |
| 30/08/2017 | 152,52 | 158,09 | 152,52 | 156,29 | +2,22% | 3,65% | 1.246.900 |
| 29/08/2017 | 151,86 | 154,16 | 151,77 | 152,89 | -0,33% | 1,57% | 888.400 |
| 28/08/2017 | 154,64 | 154,91 | 151,05 | 153,40 | +0,08% | 2,50% | 1.187.900 |